Indian firms may garner up to 50% of USFDA nod share in 2023
NEW DELHI: Indian companies are expected to secure a 48-50 percent share of approvals for new drugs from the US ...
NEW DELHI: Indian companies are expected to secure a 48-50 percent share of approvals for new drugs from the US ...
Team Blitz India NEW DELHI: Drug major Sun Pharmaceutical Industries is recalling pre-filled syringes of a drug, used to treat ...
Blitz Bureau NEW DELHI: The Supreme Court on July 14 refused to stay the CBSE's three-language policy, which was introduced...
Read moreDetails